Hepatitis C Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Hepatitis C Market Trends and Insights

Rising HCV Prevalence & Mandatory Universal Screening

Universal one-time or birth-cohort screening replaces risk-based approaches and uncovers hidden cases in rural and suburban populations. US Centers for Disease Control modelling shows that only one-third of diagnosed Americans achieved virologic cure between 2013 and 2022, underscoring latent demand for streamlined linkage-to-care pathways. Whole-population surveys in Europe reveal prevalence pockets above 1% among individuals^{[1]Kuan-Chen Pan, “Prevalence-based screening by anti-HCV reflex HCV antigen test and accessible post-screening care towards elimination of hepatitis C in rural villages,” BMC Gastroenterology, bmcgastroenterol.biomedcentral.com} born between 1965 and 1985, far exceeding prior estimates. Countries meeting the World Health Organization’s 90% diagnosis target demonstrate markedly steeper treatment adoption curves than nations still at sub-30% awareness levels. As more public health agencies set mandatory screening in primary-care and emergency-department settings, diagnostic volumes continue to rise even while the chronic prevalence rate falls. 

Government-Funded National Elimination Initiatives

Egypt’s national elimination programme treated over 4 million citizens and reached 87% cure, validating large-scale, publicly financed models. Australia, Canada, and Spain now provide unlimited DAA access through subscription or capped-payment contracts that align payer incentives with elimination targets. In the United States, a proposed USD 11 billion federal fund would cover the uninsured population and support state Medicaid treatment expansion, potentially adding 400,000 annual treatment starts by 2027. These schemes lock in predictable volumes^{[2]David W Matthews, “The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition,” Liver International, pmc.ncbi.nlm.nih.gov}, allowing manufacturers to exchange price concessions for certainty while accelerating progress toward the 2030 elimination milestone. 

Advances in Point-of-Care and Molecular Diagnostics

Cepheid’s finger-stick GeneXpert assay delivers confirmed RNA results in under an hour and boosts same-day treatment initiation rates to 84% in community clinics. Implementation studies in Vietnam indicate that a single-visit screen-confirm-treat workflow retains 92% of patients through cure, compared with 54% under conventional two-visit testing. High-throughput next-generation sequencing labs in the United Kingdom now provide real-time resistance surveillance, informing local procurement of salvage regimens. Cost per diagnosis falls as cartridge prices descend below USD 7 in tender markets, making population screening financially viable for middle-income governments.

Superior Cure Rates & Shorter Regimens of DAAs

Pan-genotypic combinations such as sofosbuvir/velpatasvir consistently exceed 95% sustained virologic response across all fibrosis stages. Pipeline agents aim to compress therapy to 2–4 weeks to improve adherence and cut pharmacy costs, with Atea Pharmaceuticals advancing Bemnifosbuvir plus Ruzasvir combination^{[3]Atea Pharmaceuticals, “Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus,” ateapharma.com} into Phase 3. High success rates, however, shorten average revenue per patient lifetime and compel firms to diversify into retreatment niches, co-morbid liver disorders, and geographic expansion. Resistance-associated substitutions emerging in 3–5% of previously treated patients underpin demand for salvage therapies, while pan-genotypic potency simplifies procurement for resource-limited buyers.

High Branded-Therapy Cost & Reimbursement Gaps

Course prices for branded pan-genotypic DAAs remain near USD 24,000 in many high-income markets, leading to restrictive payer criteria based on fibrosis stage or sobriety requirements. Out-of-pocket cost exposure discourages treatment among uninsured or under-insured populations, even where community health centres offer low-cost screening. Generic sofosbuvir/velpatasvir is available for under USD 100 in India, Pakistan, and Egypt, yet patent claws and exclusivity clauses keep list prices elevated elsewhere. The cumulative spend, including confirmatory RNA tests, fibrosis staging, and specialist visits, can exceed USD 30,000 per person, hampering uptake despite proven cost-effectiveness. 

Large undiagnosed pool & social stigma

An estimated 81% of people with chronic infection worldwide remain unaware of their status. Fear of discrimination tied to injection-drug use, incarceration history, or migrant status deters many from voluntary testing. Passive screening in primary care settings misses asymptomatic individuals, while provider bias leads to under-ordering of HCV assays for older adults without obvious risk factors. The resulting late diagnoses coincide with advanced liver disease, raising treatment complexity and healthcare costs. Community-based outreach programmes combined with anonymity-preserving rapid tests have begun to close this gap, yet stigma continues to dampen overall market penetration. 

Segment Analysis

By Component: Treatment maintains revenue dominance

Treatment accounted for 88.14% of the Hepatitis C market share in 2024, reflecting the high unit value of DAAs that sell at premium prices in many countries. Direct-acting antivirals anchored by sofosbuvir combinations generated the bulk of segment turnover, with Harvoni and Epclusa alone surpassing USD 9 billion in global sales in 2024. Pegylated-interferon/ribavirin now constitutes a single-digit niche for interferon-eligible patients, while immunomodulatory adjuncts are under investigation for non-responders. The Hepatitis C market size for treatment could reach USD 16.4 billion by 2030 if current reimbursement frameworks hold. 

Diagnosis, although smaller, is rising at a 5.73% CAGR as universal screening, antenatal testing, and prison-based programmes increase test volumes. Point-of-care antibody assays, reflex RNA cartridges, and high-throughput NAAT platforms dominate procurement tenders in Asia-Pacific and Latin America. Molecular sub-typing and resistance sequencing deliver incremental revenue by guiding personalized therapy. An integrated “test-to-treat” workflow retains patients and extends value capture across both component categories, mitigating treatment-segment contraction caused by shrinking prevalence. 

By Age Group: Baby boomers underpin demand

Adults aged 18–45 represented 62.73% of the 2024 Hepatitis C market size, a legacy of widespread transfusion-related and injection-drug transmission during the 1960s–1980s. As this cohort ages into Medicare or equivalent public coverage, payer policies increasingly cover pan-genotypic regimens without fibrosis restrictions, sustaining growth at a 4.28% CAGR. The Hepatitis C market size attached to this cohort is projected to exceed USD 10 billion by 2030. 

Patients under 18 account for a low revenue base due to limited vertical transmission; nevertheless, pediatric approvals of sofosbuvir/velpatasvir since 2024 broaden accessible therapy. Individuals over 45 contribute a stable but slower-growing share, often presenting with cirrhosis or co-morbidities that heighten monitoring costs. Age-linked pharmacokinetic shifts call for dose adjustments, creating incremental demand for real-time drug-interaction software embedded into electronic health records. 

By Channel: Decentralization accelerates

Hospitals and specialist clinics retained 65.82% of the Hepatitis C market share in 2024 owing to historic reliance on hepatologists and infectious-disease physicians for prescription and monitoring. Yet community pharmacies and retail clinics, growing at a 5.46% CAGR, are redefining patient flow by offering on-site RNA confirmation and same-day dispensing. Randomized evaluations in the United States show pharmacy-initiated treatment achieving 90.3% cure^{[4]Andrew H. Talal, “Integrated Hepatitis C–Opioid Use Disorder Care Through Facilitated Telemedicine,” JAMA, jamanetwork.com}, compared with 39.4% under referral pathways. 

Telemedicine platforms embedded in opioid-substitution clinics extend reach into rural zones, while mobile vans screen high-risk groups at festivals and homeless shelters. Diagnostic laboratories keep stable revenue via bulk testing contracts with correctional facilities and antenatal clinics. As payer networks reimburse pharmacist prescribing and remote monitoring, the Hepatitis C market is gradually shifting towards a more distributed footprint that counters capacity constraints in tertiary centres. 

Geography Analysis

North America commanded 40.19% of the Hepatitis C market share in 2024, powered by comprehensive screening mandates, premium branded pricing, and broad Medicaid coverage. However, growth moderates to a 3.36% CAGR as prevalence declines in previously untreated baby boomers. The proposed federal elimination fund, if enacted, could still add large treatment volumes by underwriting uninsured care. Canada aligns drug pricing with health-technology assessments, capping list prices, while Mexico’s Seguro Popular programme is beginning to subsidise locally manufactured generics, anchoring volume growth despite lower per-patient spend. 

Europe accounts for a sizeable share and shows a 3.08% CAGR through 2030. Joint procurement initiatives under the Beneluxa coalition and national subscription deals in Spain and Portugal have trimmed treatment course prices by 45% since 2022. The United Kingdom reports a 51.6% drop in chronic infection prevalence after integrating whole-genome surveillance with direct community outreach. Eastern European nations, backed by Global Fund transition grants, are scaling harm-reduction, testing, and treatment packages among people who inject drugs, unlocking additional diagnostic volumes. 

Asia-Pacific is the fastest-growing territory, expanding at 4.91% CAGR. China’s volume-based procurement brought down the sofosbuvir/velpatasvir price ceiling by 68% in the 2024 tender round, catalysing provincial bulk-buy orders. India’s National Viral Hepatitis Control Programme finances generics at under USD 100 per course and reimbursed more than 550,000 treatments in 2024. Malaysia, Thailand, and Vietnam deploy the “Netflix” capped-price model, facilitating mass campaigns among high-burden populations. The Hepatitis C market share derived from Asia-Pacific is expected to climb above 28% by 2030, powered by aggressive elimination goals paired with domestic manufacturing.